# US Theranostics Market > US Theranostics Market Research Report By Application (Oncology, Neurology, Cardiology, Infectious Diseases), By Technology (Genomics, Proteomics, Metabolomics, Biomarkers), By End User (Hospitals, Diagnostic Laboratories, Research Institutes) and By Product Type (Instruments, Reagents, Software) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 12.87% - **2024:** $ 1,926.96 Million - **2025:** $ 2,174.96 Million - **2035:** $ 7,300 Million - **Key Players:** Roche (CH), Thermo Fisher Scientific (US), Abbott Laboratories (US), Siemens Healthineers (DE), Bristol-Myers Squibb (US), Merck KGaA (DE), Illumina (US), Qiagen (DE), Genomic Health (US), AstraZeneca (GB) **Report ID:** MRFR/HC/18508-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-theranostics-market-20055 --- ## Market Summary ## US Theranostics Market Overview As per MRFR analysis, the US Theranostics Market Size was estimated at 1.72 (USD Billion) in 2023. The US Theranostics Market is expected to grow from 2.35 (USD Billion) in 2024 to 8.35 (USD Billion) by 2035. The US Theranostics Market CAGR (growth rate) is expected to be around 12.216% during the forecast period (2025 - 2035). ### Key US Theranostics Market Trends Highlighted The growing need for individualized therapy and developments in molecular diagnostics are driving the substantial expansion of the US theranostics market. The increasing incidence of chronic illnesses like cancer and heart disease, which call for tailored treatments that can be combined with related diagnostic procedures, is one of the major factors propelling the market. The US regulatory environment is also changing to facilitate the creation and authorization of theranostic drugs, with organizations advocating for routes that accelerate the combination of treatments and diagnostics. Clinical researchers, labs, and pharmaceutical corporations are collaborating and innovating because of this favorable atmosphere. Increased integration of AI and machine learning in diagnostic procedures, which improves accuracy and efficiency, is one opportunity to investigate in the US theranostics sector. Liquid biopsy methods are also gaining popularity since they offer non-invasive ways to identify illnesses and track how well treatments are working. As customized solutions for specialized patient populations gain traction, the focus on rare and orphan diseases further opens up opportunities for theranostics. Value-based care models, which promote the use of interventions that clearly improve patient outcomes in relation to costs, have become more and more popular in recent years. Healthcare providers are increasingly embracing these integrated approaches as a result of increased understanding of theranostics' advantages. Research and development initiatives that are in line with the particular requirements of the US healthcare system are also made easier by the growing collaborations between biotech companies and academic institutions. This general pattern suggests a changing environment in which theranostics is increasingly playing a crucial role in contemporary American medical practice. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## US Theranostics Market Drivers ### Rising Prevalence of Chronic Diseases The US Theranostics Market is experiencing significant growth due to the rising prevalence of chronic diseases, particularly cancer and cardiovascular diseases. According to the Centers for Disease Control and Prevention (CDC), chronic diseases account for 70% of deaths in the United States. With approximately 1.9 million new cancer cases projected in a recent year, organizations such as the American Cancer Society are pushing for innovative treatment methods. Theranostics, which provides individualized treatment through targeted therapies, is poised to capitalize on this urgent need. As demographic trends indicate an aging population, the demand for effective theranostic solutions is anticipated to escalate. The CDC also notes a year-on-year increase in chronic disease-related treatment costs, reinforcing the urgency for targeted and effective therapeutics that can be facilitated by theranostic advancements. ### Technological Advancements in Diagnostics The technological advancements in diagnostic tools and imaging technologies are significant drivers contributing to the growth of the US Theranostics Market. New technologies enable more precise diagnostics, thus improving patient management. The FDA has approved numerous advanced genomic testing methods, which allow for more tailored treatments based on individual patient profiles. For instance, next-generation sequencing (NGS) and liquid biopsy technologies have been instrumental in this transformation. Recent advancements reported by major health institutions indicate that these technologies can help in accurately identifying specific mutations that govern cancer treatment, leading to better patient outcomes. Such innovation not only enhances the efficacy of therapies but also supports the broader adoption of theranostics in clinical settings. ### Increased Investment in Personalized Medicine There is a growing investment focus on personalized medicine within the US healthcare sector. According to the National Institutes of Health (NIH), funding for research into personalized therapies has been steadily increasing, with billions allocated towards understanding genetic variations in diseases. Organizations like the Personalized Medicine Coalition are actively promoting the value of personalized medicine, which emphasizes the delivery of targeted therapies to patients based on their unique genetic profiles. This shift towards personalized medicine aligns perfectly with the theranostics model, which combines diagnostics and therapeutics. The increasing understanding and technological capabilities surrounding biomarkers are attracting significant investments, driving growth within the US Theranostics Market, as these investments support innovative approaches for disease treatment. ### Growing Demand for Cost-effective Healthcare Solutions With rising healthcare costs in the US, there is an increasing demand for cost-effective healthcare solutions, which theranostics can efficiently provide. The National Health Expenditure Accounts (NHEA) report indicated that healthcare spending in the US reached approximately $4.1 trillion, urging a re-evaluation of treatment strategies. Theranostics offers a cost-efficient avenue through its targeted approach, which reduces unnecessary treatments and associated costs. By ensuring that patients receive only the necessary therapies based on their specific conditions, healthcare systems can save significant funds. The integration of theranostics is increasingly seen as a solution to enhance cost-effectiveness while improving patient outcomes, making it a key driver in the growing US Theranostics Market. ## US Theranostics Market Segment Insights ### Theranostics Market Application Insights  The US Theranostics Market encompassing the Application segment from 2019 to 2032 is positioned for robust growth, driven by advancements in personalized medicine and targeted therapies. This market is characterized by significant contributions from multiple areas, including Oncology, Neurology, Cardiology, and Infectious Diseases. Oncology is particularly noteworthy as it represents a significant portion of the overall market due to the rising prevalence of cancer and the growing demand for tailored treatment options. Innovative therapies that combine diagnostics and therapeutics are being developed, yielding improved patient outcomes and ensuring that the right treatment is given to the right patient at the right time. Neurology is also gaining traction within the US Theranostics Market, spurred by increased recognition of neurological disorders such as Alzheimer's and Parkinson's disease, which require specialized diagnostics and therapeutic approaches to enhance patient management and care. Moreover, Cardiology is emphasizing the need for theranostic approaches to address heart diseases which remain among the leading causes of mortality in the United States, highlighting the significance of personalized treatment strategies to improve cardiovascular health. Infectious Diseases is rapidly evolving within the market, especially with the ongoing advancements in molecular diagnostics, which are crucial for tracking infections and guiding appropriate therapy, reflecting the surging need for precision in treatment amidst rising global health concerns. The adoption of theranostic applications across these areas is amplified by the increasing prevalence of chronic conditions, technological advancements, and the urgency for efficient healthcare solutions. The US Theranostics Market data indicates that innovative technologies such as AI and machine learning are being integrated into diagnostic tools, facilitating swift and accurate treatment decisions. Collectively, these trends underscore the multidimensional growth potential of the US Theranostics Market, propelled by the convergence of diagnostics and therapeutics across diverse medical fields. Furthermore, the ongoing investments in research and development supported by governmental health initiatives are anticipated to play a vital role in reinforcing the US position as a leader in theranostics, affecting overall market dynamics and segmental advancements in the future. The US Theranostics Market thereby lays promising groundwork for comprehensive health solutions that effectively meet the evolving demands of healthcare providers and patients alike, presenting myriad opportunities for stakeholders engaged in therapeutic innovation. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ### Theranostics Market Technology Insights The US Theranostics Market, encompassing the Technology segment from 2019 to 2032, signifies a robust evolution, with various critical fields driving innovation. Within this framework, Genomics plays an increasingly pivotal role, helping in personalized medicine by tailoring treatments based on genetic profiles. Proteomics focuses on the large-scale study of proteins, which is essential for understanding disease mechanisms and discovering biomarkers for diagnostics. Metabolomics adds another layer by analyzing chemical processes involving metabolites, thus providing valuable insights into the metabolic changes associated with diseases. Biomarkers are vital in this arena as well, serving as indicators for treatment responses and disease progression. The integration of these technologies not only enhances the understanding of complex diseases but also fosters the development of targeted therapies, contributing to improved patient outcomes. The growth in the US Theranostics Market is fueled by advancements in technology, increased investments in research, and a rise in cancer and chronic diseases, creating significant opportunities for innovation and development in these segments. ### Theranostics Market End User  Insights The US Theranostics Market exhibits a robust structure with the End User segmentation highlighting significant contributions from Hospitals, Diagnostic Laboratories, and Research Institutes. Hospitals are pivotal in this market, as they serve as the primary point of care, integrating advanced theranostic technologies into clinical workflows to enhance patient outcomes. Diagnostic Laboratories play a crucial role by providing essential testing services that facilitate personalized medicine, thus driving the demand for theranostic applications. Research Institutes are vital for innovation, focusing on developing new diagnostic and therapeutic techniques that can be translated into clinical practice. Together, these segments contribute to the overall growth of the US Theranostics Market, driven by increased healthcare spending and advancements in precision medicine, while challenges such as regulatory hurdles and the need for widespread adoption remain. With the ongoing rise in chronic diseases, the importance of theranostics is likely to grow, opening up further opportunities in this dynamic industry. The market growth in these segments underscores the significance of targeted and personalized treatments, demonstrating their impactful role in enhancing therapeutic efficacy and patient care in the United States. ### Theranostics Market Product Type  Insights The US Theranostics Market is positioned for notable growth across various product types, notably Instruments, Reagents, and Software. Instruments play a crucial role, as they facilitate precise diagnostics essential for personalized therapy, indicating their significant contribution to the healthcare sector in the US. Reagents also play a vital role by providing necessary chemical substances for therapeutic diagnostics, which enhances the accuracy of treatment plans. Meanwhile, Software is becoming increasingly important in this market, enabling data management and analysis for better decision-making regarding patient care. As the US government continues to support advances in precision medicine and theranostics through various health initiatives, there is a clear trend toward integrating these product types. Overall, the US Theranostics Market showcases a vibrant landscape driven by technological advancements and the growing emphasis on personalized medicine, fostering a supportive environment for instruments, reagents, and software to thrive. This market is characterized by opportunities for innovation and growth, aligning well with ongoing healthcare demands. ## US Theranostics Market Key Players and Competitive Insights The US Theranostics Market is characterized by its dynamic landscape, influenced by a blend of innovation, regulatory frameworks, and competitive strategies. This sector, which merges therapeutic and diagnostic advancements, has witnessed significant growth due to the rising demand for personalized medicine. Stakeholders in this market are increasingly focused on enhancing patient outcomes through the development of targeted therapies that are accompanied by predictive diagnostics, fostering a more precise treatment paradigm. The competitive environment features a mix of established pharmaceutical companies and emerging biotechnology firms, all vying for technological supremacy and market share. Investment in research and development is a crucial factor driving competition, with players continuously striving to improve their offerings through strategic collaborations, acquisitions, and the integration of advanced technologies into their product pipelines. In the context of the US Theranostics Market, Qiagen has established a robust presence marked by a commitment to providing innovative solutions that enhance the detection and characterization of diseases. The company has developed a diverse portfolio consisting of molecular diagnostics and sample preparation technologies that are pivotal for the successful implementation of theranostic approaches. Qiagen’s strengths lie in its ability to deliver high-quality products that meet regulatory standards, enabling healthcare professionals to make informed decisions regarding patient treatment. The company excels in its partnerships with other entities within the healthcare ecosystem, thereby enhancing its reach and influence in the market. This strategic positioning enables Qiagen to leverage its capabilities and maintain a competitive edge in an increasingly crowded market space. Bristol Myers Squibb is a renowned player in the US Theranostics Market, recognized for its innovative therapies and commitment to advancing patient care. The company's key products in the oncology space, particularly targeted treatments, align closely with the principles of theranostics, as they often require companion diagnostics for optimal patient selection. Bristol Myers Squibb's strengths include its extensive research footprint, which enables the continuous development of therapies informed by robust clinical data. The company has undertaken several mergers and acquisitions to bolster its capabilities and expand its portfolio, further enhancing its competitive standing within the US market. By focusing on precision medicine, Bristol Myers Squibb aims to address critical unmet needs in various therapeutic areas, thereby solidifying its role as a leader in the theranostics arena. The alignment of its product offerings with the growing demand for personalized healthcare solutions underscores its strategic vision within this vital sector. ### Key Companies in the US Theranostics Market Include ## US Theranostics Market Developments The US Theranostics Market is currently experiencing significant developments and shifts. Recently, companies like Qiagen and OncoOne have published advancements in personalized medicine, showcasing the increasing emphasis on tailored therapies based on genetic profiling. In August 2023, Guardant Health announced a partnership with Merck to enhance their precision oncology approach, focusing on liquid biopsy technology which underscores a growing trend in non-invasive diagnostic methods. Furthermore, in July 2023, NeoGenomics reported a strategic expansion of its testing services to better serve oncology providers, reflecting the rising demand for more comprehensive genomic testing solutions. In terms of financial dynamics, Roche's acquisition of GenMark Diagnostics in March 2021 has strengthened its position in molecular diagnostics, aligning with the increasing investment in theranostics. The market's valuation is projected to grow substantially as more companies like Thermo Fisher Scientific and Caris Life Sciences are ramping up R&D efforts and collaborations aimed at integrating advanced diagnostics with treatment strategies. The US regulatory landscape continues to evolve, with the FDA providing clearer pathways for approving innovative theranostic agents, fueling robust market growth in this sector. ## Theranostics Market Segmentation Insights ## Market Drivers ### Regulatory Framework Enhancements The evolving regulatory landscape in the US is playing a pivotal role in shaping the theranostics market. Recent enhancements in regulatory frameworks are designed to facilitate the approval and commercialization of innovative theranostic products. The FDA has introduced streamlined pathways for the evaluation of companion diagnostics, which are essential for the successful implementation of targeted therapies. This regulatory support is expected to expedite the development and market entry of new theranostic solutions, thereby fostering innovation within the industry. As a result, the theranostics market is likely to experience accelerated growth, driven by a more favorable regulatory environment that encourages the development of cutting-edge diagnostic and therapeutic products. ### Rising Demand for Targeted Therapies The increasing prevalence of chronic diseases in the US is driving the demand for targeted therapies, which are a cornerstone of the theranostics market. As healthcare providers seek more effective treatment options, the focus on personalized medicine is intensifying. According to recent estimates, the market for targeted therapies is projected to reach approximately $100 billion by 2026, reflecting a compound annual growth rate (CAGR) of around 8%. This trend indicates a shift towards therapies that are tailored to individual patient profiles, enhancing treatment efficacy and minimizing adverse effects. Consequently, the theranostics market is likely to benefit from this growing inclination towards precision medicine, as it aligns with the need for more effective and personalized treatment modalities. ### Technological Advancements in Diagnostics Technological innovations in diagnostic tools are significantly impacting the theranostics market. The integration of advanced imaging techniques, molecular diagnostics, and biomarker discovery is enhancing the ability to identify specific disease states and tailor treatments accordingly. For instance, the use of next-generation sequencing (NGS) has revolutionized the identification of genetic mutations, allowing for more precise therapeutic interventions. The US market for molecular diagnostics alone is expected to exceed $20 billion by 2025, indicating a robust growth trajectory. These advancements not only improve patient outcomes but also drive the demand for theranostic solutions that can provide real-time insights into treatment efficacy, thereby fostering a more personalized approach to healthcare. ### Growing Awareness of Personalized Healthcare The increasing awareness of personalized healthcare among patients and healthcare providers is significantly influencing the theranostics market. As patients become more informed about their treatment options, there is a growing demand for therapies that are tailored to their unique genetic and phenotypic profiles. This shift in patient expectations is prompting healthcare providers to adopt more personalized approaches to treatment, thereby driving the adoption of theranostic solutions. Surveys indicate that over 70% of patients express a preference for personalized treatment options, which is likely to propel the growth of the theranostics market. This trend underscores the importance of aligning therapeutic strategies with individual patient needs, ultimately enhancing treatment efficacy and patient satisfaction. ### Increased Investment in Research and Development Investment in research and development (R&D) within the US healthcare sector is a critical driver for the theranostics market. Pharmaceutical companies and biotech firms are allocating substantial resources to develop innovative theranostic products that can enhance treatment precision. In 2025, R&D spending in the biopharmaceutical sector is projected to reach approximately $200 billion, reflecting a commitment to advancing personalized medicine. This influx of funding is likely to accelerate the development of novel theranostic agents, which can provide both diagnostic and therapeutic benefits. As a result, the theranostics market is poised for growth, driven by the continuous evolution of R&D initiatives aimed at improving patient care and treatment outcomes. ## Future Outlook The [Theranostics Market](https://www.marketresearchfuture.com/reports/theranostics-market-8057) is projected to grow at a 12.87% CAGR from 2025 to 2035, driven by advancements in personalized medicine, increased R&D investments, and rising demand for targeted therapies. **New opportunities:** - Development of integrated diagnostic-therapeutic platforms - Expansion of personalized treatment plans in oncology - Investment in AI-driven data analytics for patient stratification By 2035, the theranostics market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Application: Oncology (Largest) vs. Neurology (Fastest-Growing) The US theranostics market is witnessing a diverse distribution among its major applications, with oncology leading the charge. This segment commands a significant share due to the increasing prevalence of cancer and the subsequent demand for precision medicine. Following oncology, neurology is becoming an important player, showing robust growth driven by advancements in neurotherapeutics and diagnostics tailored for neurological disorders. Cardiology and infectious diseases also contribute to the market, but their shares remain comparatively smaller. In terms of growth trends, the oncology segment's dominance is fueled by innovations in targeted therapies and biomarker testing, which improve treatment outcomes. Conversely, the neurology segment is gaining momentum, characterized as the fastest-growing due to rising incidences of neurological conditions such as Alzheimer's and Parkinson's disease. The need for personalized treatment strategies and improved diagnostic tools in these areas is driving investment and research in theranostics for neurology, indicating a transformative shift in the market dynamics. Oncology (Dominant) vs. Neurology (Emerging) Oncology remains the dominant segment in the US theranostics market, characterized by a diverse range of therapeutic and diagnostic applications focused on various types of cancers. This segment benefits from ongoing research and advancements in precision medicine, enhancing patient outcomes through personalized treatment plans. The strong pipeline of innovative therapies and the increasing patient population in need of targeted oncology treatments ensure its continued leadership. Neurology, while traditionally smaller in market share, is emerging rapidly due to a rising awareness of neurological disorders. This segment is characterized by a growing range of theranostic solutions aimed at early diagnosis and effective treatment of conditions like epilepsy, multiple sclerosis, and neurodegenerative diseases. Investments in research and collaborations between biotech firms and academic institutions are fostering new developments, making neurology a vital area to watch as it evolves within the landscape of theranostics. ### By Technology: Genomics (Largest) vs. Proteomics (Fastest-Growing) The US theranostics market displays a diverse array of technologies, with genomics commanding the largest share. Genomics is consistently leveraged for its precision and ability to identify genetic predispositions toward diseases. Conversely, proteomics is emerging rapidly, capitalizing on advancements in biological markers that inform therapeutic strategies. This juxtaposition highlights a market dynamic influenced by ongoing research and innovations in biosciences. In terms of growth trends, the shift towards personalized medicine is propelling proteomics into a position of prominence, indicative of an increased focus on biomarker discovery. Key drivers such as technological innovations, rising incidences of chronic diseases, and favorable government initiatives bolster this segment's growth. As the industry shifts towards more tailored treatments, both genomics and proteomics are set to play pivotal roles in shaping therapeutic options. Technology: Genomics (Dominant) vs. Proteomics (Emerging) Genomics stands out as a dominant force in the US theranostics market due to its extensive applications in understanding genetic diseases and tailoring individualized treatment plans. It has established a comprehensive framework that supports the identification of genomic variations linked to diseases, thereby influencing therapeutic decision-making. On the other hand, proteomics is categorized as an emerging technology that harnesses proteins for biomarker discovery and disease diagnostics. It is rapidly evolving to meet the challenges of more complex disease mechanisms, ensuring that treatments are not only effective but also personalized. As innovation in sampling and analysis methods progresses, proteomics is gaining ground and promises to complement the insights provided by genomics in the future. ### By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing) The US theranostics market shows a diversified segment distribution among its end users, with hospitals holding the largest market share. Diagnostic laboratories follow closely, exhibiting a notable presence in the market. Research institutes, while integral to the development of new theranostics, account for a smaller share compared to hospitals and laboratories. The extensive healthcare infrastructure and patient volume in hospitals significantly contribute to their dominant position within the market. Growth trends in the US theranostics market reveal a strong expansion in the diagnostic laboratories segment, driven by increasing demand for rapid testing and personalized medicine. Factors such as technological advancements, rising healthcare expenditures, and a shift towards precision medicine are propelling this segment's growth. Simultaneously, hospitals continue to adapt by integrating theranostic solutions, ensuring they remain at the forefront of patient care and treatment efficacy. Hospitals (Dominant) vs. Research Institutes (Emerging) Hospitals play a dominant role in the US theranostics market due to their comprehensive resources and facilities, enabling them to implement advanced diagnostic and therapeutic solutions effectively. They cater to a large patient base, thus driving significant demand for theranostic services. In contrast, research institutes are emerging players that focus on the innovation and development of new theranostic applications. These institutes primarily engage in research activities that contribute to breakthroughs in personalized medicine and targeted therapies, making them crucial for future market growth. As they collaborate with hospitals and diagnostic laboratories, their influence in the market is steadily increasing. ### By Product Type: Reagents (Largest) vs. Instruments (Fastest-Growing) In the US theranostics market, reagents hold the largest market share, driven by their critical role in various diagnostic tests and treatment options. The demand for high-quality reagents continues to surge due to advancements in precision medicine and personalized therapies, making them integral to the therapeutic landscape. Instruments, while currently smaller in market share, are experiencing rapid growth thanks to innovations in technology that enhance diagnostic capabilities and streamline workflows. The growth trend for instruments is primarily influenced by increasing investments in healthcare infrastructure and the rapid development of automated technologies that improve efficiency. Furthermore, the solid push towards early disease detection and monitoring is creating a favorable environment for instruments. As more healthcare providers adopt sophisticated diagnostic tools, the scope of instruments in theranostics is set to expand significantly in the coming years. Reagents (Dominant) vs. Software (Emerging) Reagents are the dominant players in the US theranostics market, characterized by a well-established production process and significant demand across various diagnostic applications. Their versatility allows them to be utilized in multiple therapeutic areas, making them indispensable in modern healthcare. In contrast, software solutions are emerging as critical components, enabling better data management, analysis, and integration of complex diagnostic information. While reagents dominate the market, software is gaining traction as a key enabler of personalized medicine through its capacity to enhance interpretation of results and support clinical decision-making. The convergence of traditional reagents and innovative software solutions is likely to drive future growth and transformation in the market. ## Competitive Benchmarking The theranostics market exhibits a dynamic competitive landscape characterized by rapid innovation and strategic collaborations. Key growth drivers include the increasing demand for personalized medicine, advancements in biomarker discovery, and the integration of artificial intelligence (AI) in diagnostic processes. Major players such as Roche (CH), Thermo Fisher Scientific (US), and Abbott Laboratories (US) are strategically positioned to leverage these trends. Roche (CH) focuses on enhancing its diagnostic capabilities through continuous investment in R&D, while Thermo Fisher Scientific (US) emphasizes partnerships to expand its product offerings. Abbott Laboratories (US) is actively pursuing digital transformation initiatives to improve patient outcomes, collectively shaping a competitive environment that prioritizes innovation and strategic alliances. In terms of business tactics, companies are increasingly localizing manufacturing to enhance supply chain resilience and reduce operational costs. The market structure appears moderately fragmented, with several key players exerting significant influence. This fragmentation allows for a diverse range of products and services, fostering competition that drives innovation. The collective influence of these major players is evident in their ability to set industry standards and shape market trends through strategic initiatives. In October 2025, Roche (CH) announced a collaboration with a leading AI firm to develop advanced diagnostic tools that utilize machine learning algorithms for more accurate patient stratification. This strategic move is likely to enhance Roche's competitive edge by integrating cutting-edge technology into its existing product portfolio, thereby improving diagnostic accuracy and patient outcomes. The collaboration underscores the importance of technological integration in the current market landscape. In September 2025, Thermo Fisher Scientific (US) launched a new line of theranostic assays aimed at oncology applications, which are designed to provide real-time insights into treatment efficacy. This launch is significant as it not only expands Thermo Fisher's product range but also positions the company as a leader in the oncology theranostics segment, catering to the growing demand for personalized cancer therapies. The introduction of these assays reflects a strategic focus on addressing unmet clinical needs in oncology. In August 2025, Abbott Laboratories (US) entered into a strategic partnership with a biotechnology firm to co-develop a novel theranostic platform that combines diagnostics and therapeutics for chronic diseases. This partnership is indicative of Abbott's commitment to innovation and its recognition of the need for integrated solutions in healthcare. By aligning with a biotechnology firm, Abbott aims to enhance its capabilities in developing comprehensive treatment options, thereby strengthening its market position. As of November 2025, current competitive trends in the theranostics market are heavily influenced by digitalization, sustainability, and AI integration. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident. Moving forward, competitive differentiation will likely hinge on the ability to innovate and deliver integrated solutions that meet the evolving needs of healthcare providers and patients. ## Recent News & Developments The US Theranostics Market is currently experiencing significant developments and shifts. Recently, companies like Qiagen and OncoOne have published advancements in personalized medicine, showcasing the increasing emphasis on tailored therapies based on genetic profiling. In August 2023, Guardant Health announced a partnership with Merck to enhance their precision oncology approach, focusing on liquid biopsy technology which underscores a growing trend in non-invasive diagnostic methods. Furthermore, in July 2023, NeoGenomics reported a strategic expansion of its testing services to better serve oncology providers, reflecting the rising demand for more comprehensive genomic testing solutions. In terms of financial dynamics, Roche's acquisition of GenMark Diagnostics in March 2021 has strengthened its position in molecular diagnostics, aligning with the increasing investment in theranostics. The market's valuation is projected to grow substantially as more companies like Thermo Fisher Scientific and Caris Life Sciences are ramping up R&D efforts and collaborations aimed at integrating advanced diagnostics with treatment strategies. The US regulatory landscape continues to evolve, with the FDA providing clearer pathways for approving innovative theranostic agents, fueling robust market growth in this sector. ## Report Scope | MARKET SIZE 2024 | 1926.96(USD Million) | | --- | --- | | MARKET SIZE 2025 | 2174.96(USD Million) | | MARKET SIZE 2035 | 7300.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 12.87% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Roche (CH), Thermo Fisher Scientific (US), Abbott Laboratories (US), Siemens Healthineers (DE), Bristol-Myers Squibb (US), Merck KGaA (DE), Illumina (US), Qiagen (DE), Genomic Health (US), AstraZeneca (GB) | | Segments Covered | Application, Technology, End User, Product Type | | Key Market Opportunities | Integration of artificial intelligence in diagnostic processes enhances precision in the theranostics market. | | Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the theranostics market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US theranostics market in 2024?** A: The US theranostics market was valued at $1926.96 Million in 2024. **Q: What is the projected market valuation for the US theranostics market by 2035?** A: The projected valuation for the US theranostics market is $7300.0 Million by 2035. **Q: What is the expected CAGR for the US theranostics market during the forecast period 2025 - 2035?** A: The expected CAGR for the US theranostics market during the forecast period 2025 - 2035 is 12.87%. **Q: Which application segment holds the highest valuation in the US theranostics market?** A: The oncology application segment holds the highest valuation, with a range from $800.0 Million to $3000.0 Million. **Q: What are the key technology segments in the US theranostics market?** A: Key technology segments include genomics, proteomics, metabolomics, and biomarkers, with biomarker valuation reaching $726.96 Million to $2800.0 Million. **Q: Which end user segment is projected to have the highest growth in the US theranostics market?** A: The hospitals end user segment is projected to grow significantly, with a valuation range from $800.0 Million to $3000.0 Million. **Q: Who are the leading players in the US theranostics market?** A: Leading players in the US theranostics market include Roche, Thermo Fisher Scientific, Abbott Laboratories, and Bristol-Myers Squibb. **Q: What is the valuation range for the reagents product type in the US theranostics market?** A: The reagents product type has a valuation range from $800.0 Million to $3000.0 Million. **Q: How does the performance of the neurology segment compare to other application segments?** A: The neurology segment has a valuation range from $400.0 Million to $1500.0 Million, indicating lower performance compared to oncology. **Q: What is the significance of the software product type in the US theranostics market?** A: The software product type is valued between $626.96 Million and $2300.0 Million, highlighting its growing importance in the market. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-theranostics-market-20055*